Pharmaresearch Raises 200 Billion KRW from Global Private Equity Fund
Planned for Use in M&A
Pharmaresearch announced on the 5th that it has decided to conduct a third-party allotment paid-in capital increase to raise approximately 200 billion KRW for operating funds and other purposes.
As a result of the paid-in capital increase, 1,175,647 new shares will be issued. The price per share is 170,119 KRW.
The third-party allotment recipient is 'Polish Company Limited,' a special purpose company established by the European private equity firm CVC Capital. Pharmaresearch plans to use the investment funds for strategic overseas mergers and acquisitions (M&A) and to provide services by establishing local subsidiaries in key markets. Additionally, the investment will be used for research and development (R&D) to develop new products and enhance existing ones.
Hot Picks Today
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- [Tomorrow's Weather] Rain Across the Country Brings Relief from Heat...Caution Advised for Strong Winds
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Pharmaresearch stated, "Considering the securing of partnerships for global expansion, discovery of new growth engines, investor intentions, realization capabilities, and timing, we have finally selected Polish Company Limited."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.